ContextVision AB: Transactions made under the buy-back programme

Summary by AI BETAClose X

ContextVision AB executed further transactions under its share buy-back program, initially announced on September 3rd with a maximum value of NOK 10,000,000 and up to 4,000,000 shares. From October 24th to November 3rd, 2025, the company bought back 421,548 shares at a weighted average price of NOK 4.5076, for a total transaction value of NOK 1,905,419.64. This includes 368,649 previously disclosed buy-backs at NOK 4.5284, totaling NOK 1,672,737.48. The daily aggregated volume ranged from 1,347 to 11,664 shares, with weighted average daily prices between NOK 4.3300 and NOK 4.4854. Following these transactions, ContextVision holds 1,799,710 of its own shares, representing 2.33% of the share capital.

Disclaimer*

Oslo, 3 November – On 3 September, ContextVision AB (“ContextVision” or the “Company”) announced a share buy-back programme of up to NOK 10,000,000, with a maximum of 4,000,000 shares, in the period from 5 September 2025 to 5 March 2026.
DNB Carnegie, acting under the mandate from ContextVision, has carried out the following transactions under the buy-back programme:

DateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)
2025-10-2411 6644,485451 876,26
2025-10-273 5814,468015 941,18
2025-10-281 3474,44386 005,06
2025-10-2910 0864,404144 378,40
2025-10-3010 2154,341344 485,30
2025-10-3111 3114,330048 976,63
2025-11-034 7884,351721 019,32
Previously disclosed buy-buys under the programme (accumulated)368 6494,52841 672 737,48
Accumulated under the buy-back programme421 5484,50761 905 419,64

 
Following the completion of the above transactions, ContextVision owns a total of 1 799 710 of own shares, corresponding to 2,33% of ContextVision’s share capital.

An overview of all transactions made under the buy-back programme that have been carried out during the abovementioned time period is attached to this report and available at www.newsweb.no

This is information that ContextVision is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Richard Hallström, CFO, on the time and date provided.
 
For further information, please contact:
Richard Hallström, CFO
Email: richard.hallstrom@contextvision.com
 
About ContextVision AB:
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.

UK 100

Latest directors dealings